Breast Cancer Clinical Trial

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Summary

To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Postmenopausal women with a diagnosis of hormone receptor positive advanced breast cancer
HbA1c <5.7%

Exclusion Criteria:

Previous treatment for advanced disease

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

219

Study ID:

NCT00372996

Recruitment Status:

Terminated

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 40 Locations for this study

See Locations Near You

UCSD Medical Center - La Jolla
La Jolla California, 92037, United States
UCSD Moores Cancer Center
La Jolla California, 92093, United States
UCSD Medical Center - Hillcrest
San Diego California, 92103, United States
Washington Cancer Institute (WCI) at Washington Hospital Center (WHC)
Washington District of Columbia, 20010, United States
Florida Cancer Research Institute
Davie Florida, 33328, United States
Florida Cancer Research Institute
Plantation Florida, 33324, United States
Central Baptist Hospital
Lexington Kentucky, 40503, United States
Lexington Oncology Associates
Lexington Kentucky, 40503, United States
Bluegrass Hematology/Oncology, PSC
Lexington Kentucky, 40504, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Bringham and Women's Hospital
Boston Massachusetts, 02115, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02115, United States
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States
Dana-Farber Cancer Institute (DFCI)
Boston Massachusetts, 02215, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 2215, United States
University of Minnesota Medical Center-Fairview, Riverside Campus
Minneapolis Minnesota, 55454, United States
University of Minnesota Cancer Center
Minneapolis Minnesota, 55455, United States
University Of Minnesota Medical Center
Minneapolis Minnesota, 55455, United States
Alamance Regional Medical Center - Cancer Center
Burlington North Carolina, 27215, United States
Duke University Medical Center - Morris Cancer Center Clinics
Durham North Carolina, 27710, United States
Duke University Medical Center- Department of Medicine Oncology
Durham North Carolina, 27710, United States
Duke University Medical Center-Duke Cancer Center
Durham North Carolina, 27710, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
Duke University School Of Medicine
Durham North Carolina, 27710, United States
Texas Oncology - PA Collins Building 5th Floor
Dallas Texas, 75246, United States
Baylor College Of Medicine (Bcm)
Houston Texas, 77030, United States
Baylor College of Medicine Breast Center
Houston Texas, 77030, United States
Fletcher Allen Healthcare
Burlington Vermont, 05401, United States
Fletcher Allen Health Care
Burlington Vermont, 05401, United States
Fletcher Allen Hospital MCHV Campus
Burlington Vermont, 05401, United States
Pharmacist, Investigational Drug Service
Burlington Vermont, 05401, United States
Fletcher Allen Healthcare
Burlington Vermont, 05405, United States
Fletcher Allan Health Care
Burlington Vermont, 5401, United States
Policlinica Privada Site La Plata S.A.
La Plata Buenos Aires, B1902, Argentina
Breast Clinica de la Mama
La Plata Buenos Aires, B1902, Argentina
Policlinica Privada Site
La Plata Buenos Aires, B1902, Argentina
Policlinica Privada Site La Plata S. A.
La Plata Buenos Aires, , Argentina
Instituto de Investigaciones Clinicas
Rosario Santa Fe, S2000, Argentina
Centro Oncologico Rosario
Rosario Santa Fe, S2000, Argentina
Centro Oncologico De Rosario
Rosario Santa Fe, S2000, Argentina
Centro Oncologico
Rosario Santa Fé, S2000, Argentina
Hospital Italiano Cordoba
Cordoba , X5004, Argentina
UZ Gasthuisberg, Medische Oncologie
Leuven , 3000, Belgium
UZ Gasthuisberg
Leuven , 3000, Belgium
Oncologisch Centrum GZA
Wilrijk , 2610, Belgium
Jewish General Hospital
Montreal QC, H3T 1, Brazil
Instituto Nacional de Cancer - HCII
Santo Cristo Rio de Janeiro, RJ 20, Brazil
Hospital Sao Lucas da PUCRS
Porto Alegre Rio Grande do Sul, 90610, Brazil
Instituto Nacional DO Cancer - INCA
Rio de Janeiro RJ, 20560, Brazil
Clínica de Oncologia de porto Alegre Sociedade Simples ltda.
Porto Alegre RS, 90430, Brazil
Hospital Sao Lucas da PUCRS
Porto Alegre RS, 90610, Brazil
Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo Instituto Central
Sao Paulo SP, 05403, Brazil
Centro de Pesquisa em Oncologia - CPO
Porto Alegre , 90610, Brazil
Instituto Nacional do Cancer
Rio De Janeiro , RJ 20, Brazil
Cross Cancer Institute
Edmonton Alberta, T6G 1, Canada
Sir Mortimer B. Davis - Jewish General Hospital
Montreal Quebec, H3T 1, Canada
Dipartimento di Medicina, Divisione di Oncologia Medica, Istituto Europeo di Oncologia
Milano , 20141, Italy
Divisione di Oncologia
Napoli , 80131, Italy
Uo Oncologia Medica 2 Regione Del Veneto Istituto Oncologico Veneto IRCCS Ospedale Busonera
Padova , 35128, Italy
VU University Medical Center
Amsterdam , 1081 , Netherlands
Malmö University Hospital
Malmo , 205 0, Sweden
St Mary's Hospital NHS Trust
London , W2 1N, United Kingdom
Imperial College Healthcare NHS Trust - Charing Cross Hospital
London , W6 8R, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

219

Study ID:

NCT00372996

Recruitment Status:

Terminated

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider